Clinical Trial

A Phase IIII Study of AL8326 in Small Cell Lung Cancer

Name: A Phase IIII Study of AL8326 in Small Cell Lung Cancer — clinical trial record (NCT06247605)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This is a multicenter, randomized, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of AL8326 tablets in small cell lung cancer (SCLC) patients with disease progression or recurrence after receiving at least second-line treatment regimens.

Trial Details

NCT Number	NCT06247605
Lead Sponsor	Advenchen Laboratories Nanjing Ltd.
Conditions	Small Cell Lung Carcinoma
Enrollment	243 participants
Start Date	2023-10-26
Primary Completion	2028-07 (estimated)
Study Completion	2029-07 (estimated)
Updated on ClinicalTrials.gov	2024-02-08